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Background: The trend of extended-spectrum beta-lactamases producing Escherichia coli (ESBL-EC) is increasing in
Nepal. Limited studies have been reported investigating ESBL types and carbapenemases in E. coli.
Methods: A cross sectional study was conducted between June 2012 to January 2013 in Kathmandu Medical College
and Teaching Hospital, Nepal. Non-repetitive clinical samples from out-patient department (OPD) and Intensive Care
Units (ICU) were processed for bacteriological culture and identification of E. coli. Antibiotic susceptibility test, screening
and phenotypic confirmation for ESBLs and carbapenemases and PCR (blaCTX-M, blaSHV and blaTEM-type ESBLs, blaVIM,
blaIMP and blaNDM-1-type carbapenemases, and class 1 integron element integrase gene) were performed. Clones were
resolved by PCR-Randomly Amplified Polymorphic DNA.
Results: Out of 332 non-repetitive clinical specimens processed for culture and identification 160 (48.2%) were culture
positive. Of which, 93 (58.1%) were E. coli. Of these, 24 (25.8%) were phenotypically confirmed as ESBL-EC and 3
(12.50%) of 24 ESBL-EC were carbapenemase producers. blaCTX-M-type ESBL was most common (23, 95.8%) followed by
blaTEM (7, 29.2%) and blaSHV (3, 12.5%). blaVIM, blaIMP and blaNDM-1 were present in 3, 2 and 2 ESBL-EC, respectively. Class
1 integron element was present in 18 (75.0%) ESBL-EC. Nine isolates possessed more than one type of beta-lactamases.
Interestingly, all carbapenemase producers were isolated form ICU and co-existence of blaCTX-M, blaSHV, blaTEM, blaIMP,
blaVIM and blaNDM-1 beta-lactamases was documented in one ESBL-EC (EC104). All most all isolates had different RAPD
patterns.
Conclusions: For the first time in Nepal, high prevalence of blaCTX-M-type ESBL and co-existence of ESBLs and
carbapenemases has been described. Continuous monitoring and surveillance and proper infection control and
prevention practices will limit the further spread of these super-bugs within this hospital and beyond.
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Escherichia coli is associated with numerous infections
such as urinary tract infection, surgical site infection,
skin and soft tissues infection, bacteraemia, pneumonia
etc [1-3]. These infections are common among out-
patient and Intensive Care Unit (ICU) admitted patients
[4]. ICU patients are subjected to numerous invasive
procedures and are susceptible to ICU acquired infections
(IAI) and Escherichia coli is a common pathogen [5].
Extended-spectrum beta-lactam antibiotics-third gener-
ation cephalosporins- are commonly used for treating* Correspondence: badri_bishal@yahoo.com
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unless otherwise stated.infections caused by Escherichia coli in Kathmandu
Medical College and Teaching Hospital (KMCTH), Nepal.
These antibiotics are less effective as Extended-spectrum
beta-lactamase producing isolates of E. coli (ESBL-EC) is
increasing in this institution [6]. Carbapenems are current
choice for treating the infection caused by ESBL-EC how-
ever, emergence of carbapenem-resistant isolates has also
been noticed [7]. Hence, the successful treatment outcome
of E. coli infections is seriously tempered by these ESBL-
and carbapenem-resistance.
Increase trends of ESBL and carbapenem-resistance
over the past two decades has been noticed globally and
also in Nepal [6,8,9]. Several variants of ESBLs; TEM,
SHV and CTX-M have been described however; there is
paucity in studies of ESBL and carbapenemases typesLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Primers used in this study
Name of
the primer





























Note: *S = G or C, ≠Y = C or T, ¥R = A or T.
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tect common ESBLs (blaTEM, blaSHV, and blaCTX-M)
and carbapenemases (blaIMP, blaVIM, and blaNDM) in
ESBL-EC isolated from Kathmandu Medical College
Teaching Hospital, Nepal. Here, we describe high
prevalence of blaCTX-M type ESBL and carbapenemases
producing E. coli and co-existence of ESBLs and carba-
penemases in these isolates.
Methods
Specimens, inclusion criteria and identification of E. coli
isolates
Non-repetitive clinical specimens (mid-stream urine,
pus, discharge from surgical wound, endotracheal secre-
tions, sputum, catheter tips etc.) received as part of
standard patient care investigation from Intensive Care
Unit (ICU) and out-patient department (OPD) in
Kathmandu Medical College and Teaching Hospital be-
tween June 2012 to January 2013 were processed for cul-
ture and antibiotic susceptibility testing from patients
attending OPD and admitted in ICU were included in
the study. The patients already on antibiotics were ex-
cluded based on the history of antibiotics mentioned in
the culture investigation form. E. coli isolates were iso-
lated and identified using standard microbiological tech-
nique [5].
Identification of E. coli isolates
All specimens were cultured on MacConkey and blood
agar and incubated overnight at 37°C in the department
of microbiology, KMCTH using standard microbio-
logical technique [10]. On grown lactose fermenting col-
onies biochemical tests was performed to identify E. coli.
Anti-microbial susceptibility technique
Kirby-Bauer disk diffusion test was performed on identi-
fied E. coli on Mueller-Hinton agar according to Clinical
and Laboratory Standards Institute guidelines (CLSI) [11].
The following antibiotic disks procured from Hi Media
Pvt. Ltd., India were used; ampicillin (20 μg) nalidixic acid
(30 μg), amoxycillin (30 μg), amoxycillin-clavulinic acid
(30 μg/10 μg), cefepime (30 μg), cefotaxime (30 μg), ceftri-
axone (30 μg) and ceftazidime (30 μg), amikacin (30 μg),
tobramycin (30 μg), gentamycin (10 μg) and imipenem
(10 μg).
Screening and phenotypic confirmation of ESBL and
carbapenemase producers
The screening for ESBLs producers were performed
using cefotaxime (30 μg), ceftazidime (30 μg) and ceftri-
axone (30 μg) and interpreted based on CLSI guidelines
[11]. Phenotypic confirmation of ESBL producers were
confirmed using ceftazidime disc (30 μg) alone and in
combination with clavulanic acid (10 μg). Similarly,imipenem resistant E. coli were confirmed for carbape-
nemase production by modified Hodge test [11].
Genotype confirmation of ESBLs and carbapenemases
Crude DNA was extracted from pure culture of E. coli.
Briefly, fresh culture of the test organism was suspended in
500 μl of saline, vortexed, boiled for 10 minutes, cellular
debris was removed by centrifugation at 11,000 rpm for
5 min and supernatant was used as DNA template for PCR
analysis. PCR amplification of the drug resistance genes
like blaTEM, blaSHV, blaCTX-M, blaIMP, blaVIM and blaNDM-1
was performed using gene specific primers (Table 1) and
amplification profiles described earlier [12-14]. The PCR
was performed in Genesis Laboratory and Research,
Kathmandu, Nepal.
Controls
ESBL negative E. coli (ATCC 25922), ESBL positive K.
pneumoniae (ATCC 700603) and Imipenemase producing
Pseudomonas aeruginosa were used as controls in disk dif-
fusion test, screening and confirmation tests. Multiple
strains of P. aeruginosa genetically characterized to pro-
duce TEM, CTX-M, SHV, IMP, VIM and NDM-1 were
used as positive controls for PCR.
Clonal analysis
Polymerase Chain Reaction-Randomly Amplified Poly-
morphic DNA (PCR-RAPD) was to study the clonal na-
ture of these isolates as described previously [13].
Data analysis and ethical approval
The data is presented in frequency and percentages.
The study was approved by the Institutional Ethical
Table 2 Distribution of ESBL, carbapenemase and IntI1 in ESBL producing E. coli
ESBL producing E. coli blaCTX-M blaSHV blaTEM blaNDM-1 blaIMP blaVIM IntI 1
EC17, -23, -42, -103, -105, -106, -108, -205, -208,-209 + - - - - - +
EC206, -207, -210, -211 + - - - - - -
EC98, -102 + + - - - - +
EC202, -204 + - + - - - +
EC203, -212 + - + - - - -
EC100 + - + + - + +
EC104 + + + + + + +
EC107 + - + - + + +
EC201 - - - - - - +
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Results
During the study period, 332 non-repetitive clinical sam-
ples [n = 292 (OPD) and n = 40 (ICU)] were processed
and 160 samples (48.2%) [n = 130 (OPD) and n = 30
(ICU)] were culture positive. These specimens were re-
ceived from urinary tract infections (110, 68.8%), respira-
tory tract infections (19, 11.9%), surgical site infection
(16, 10.0%), skin and soft tissue infection (12, 7.5%) and
blood stream infection (3, 1.9%) and E. coli was predom-
inant pathogen (93, 58.1%). E. coli were derived mostly
from urinary tract infection (80, 86.0%). Of which, 24
(25.8%) were phenotypically confirmed as ESBL-EC among
which 10 ESBL producing isolates were from ICU. All
ESBL-EC were found to be resistant to nalidixic acid,
amoxycillin, cefepime, cefotaxime, ceftriaxone and ceftazi-
dime. ESBL-EC were also resistant to amoxicillin-clavulinic
acid (23, 95.8%), cotrimoxazole (21, 87.5%), imipenem
(3, 12.5%), gentamicin (2, 8.3%), amikacin (1, 4.2%) and
tobramycin (1, 4.2%).
blaCTX-M was the most prevalent ESBLs (23, 95.8%)
followed by blaTEM (7, 29.2%) and blaSHV (3, 12.5%)
(Table 2). Among ESBL-EC, 3 (12.5%) (EC100, EC104Figure 1 Gel electrophoresis of PCR amplicons of RAPD patterns. Lane M: Molecular weight marker (1 kb+ Invitrogen). Lane 1-24: E.coli
isolates, EC17, EC23, EC42, EC98, EC100, EC102, EC103, EC104, EC105, EC106, EC107, EC108, EC201, EC202, EC203, EC204, EC205, EC206, EC207,
EC208, EC209, EC210, EC211 and EC212.and EC107) isolates were screened and confirmed as
cabapenemase producers. All these 3 isolates were from
ICU. blaVIM was present in all of these isolates , blaNDM-1
was present in 2 isolates (EC100 and EC104) and blaIMP
was present in 2 isolates (EC104 and EC 107). Strikingly,
carbapenemase harboring isolates were found to contain
more than one resistant gene under the study. Co-
existence of ESBLs and carbapenemases among ESBL-EC
was variable (Table 2). An EC104 harboured all resistant
genes investigated. Class 1 integron element was prevalent
among the ESBL producers (18, 75.0%).
All isolates of E. coli were subjected for RAPD. The
isolates showed different RAPD patterns. Isolates EC106
& EC107 possessed similar RAPD patterns and rest of
the isolates had individual RAPD patters (Figure 1).
Discussion
E. coli is responsible for numerous infections and is fre-
quently involved in sepsis and other infections in OPD
and critically ill patients in Intensive Care Units (ICU)
[5,15]. The emergence of ESBL producing E. coli (ESBL-
EC) is a real challenge for infectious disease medicine as
these bugs are increasingly detected worldwide particu-
larly in ICU [15,16]. ESBL-EC infections ultimately re-
sults in unavoidable treatment outcomes and increases
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infections were caused by E. coli. Of these infections,
25.8% (24/93) and 3.2% (3/93) were caused by ESBL-
EC and carbapenemase producing E. coli, respectively.
Frequency of isolation of E. coli is also common in
ICUs elsewhere however infections due to ESBL-EC
and carbapenemase producer vary among different
geographical regions [5,17]. Since 2000, the already
ubiquitous E. coli has emerged as major ESBL produ-
cing organism. In 2007, already 79% of E. coli isolates
collected in India were positive for ESBLs, with almost
identical prevalence in hospital and community [18],
55% in China and 50.8% in Thailand [17]. ESBL-EC in
ICU are increasing than general wards and out patients
in this institution which is worrisome [6].
We have detected a variety of beta-lactamases among
the isolates of E. coli namely blaCTX-M, blaTEM, blaSHV-
type enzymes. The blaCTX-M type was the most prevalent
ESBL (n = 23). The incidence of this enzyme surpasses
those of blaTEM and blaSHV-type ESBLs in most locales
worldwide [19] and also in our study. The wider spread
of blaCTX-M is also due to over use of third generation
cephalosporins which has selected these strain. Some of
the blaCTX-M types are also associated with mobile gen-
etic elements like class 1 integron element which con-
tributes to its wider spread [20]. This was also evident in
this study as 18 out of 23 blaCTX-M positive isolates pos-
sessed class 1 integron element. However, the location of
blaCTX-M in class 1 element was not studied and needs
further investigation. One of the isolate was ESBL-EC on
screening and phenotypic test but didn’t possessed
CTX-M, TEM and SHV enzymes, other ESBLs (AmpC)
or other mechanisms could be possible [21].
The prevalence of blaCTX-M, blaTEM and blaSHV- type
ESBLs in E. coli is variable across different cities, coun-
tries and regions [22]. The prevalence of blaCTX-M and
blaSHV genes was reported as 83% and 28%, respectively
in ESBL-EC in New York [23] and 22.7% and 9.1%, re-
spectively in ESBL-EC in Turkey [24]. Similarly, preva-
lence of blaCTX-M and blaTEM was 11% and 50%,
respectively in Pakistan [25]. However, the blaCTX-M has
displaced other ESBLs in this geographical location as
demonstrated in this study and also in Eastern Europe,
South America, Japan and India [26].
The important finding in the study was the co-
existence of different ESBLs and carbapenemases in the
same isolate. Of 24 ESBL-EC, 9 (37.5%) possessed more
than one ESBLs. Study in Taiwan reported co-existence
of two or more kinds of ESBL in 40.6% of ESBL-EC [27].
Similarly, co-existence of blaCTX-M and blaTEM was
found in 52.6% of French ESBL-EC [28]. Co-existence of
NDM-1 and OXA-76 has been described in Klebsiella
pneumoniae isolates from Nepal [29]. Carbapenemase
producers were found to harbor carbapenemases co-existing with ESBLs. Each of EC104, EC100 and EC107
possessed blaCTX-M + blaTEM + blaSHV + blaNDM-1 +
blaIMP + blaVIM, blaCTX-M + blaSHV + blaNDM-1+ blaVIM
and blaCTX-M + blaTEM + blaIMP + blaVIM, respectively.
This co-existence of 6 beta-lactamases in EC104 was
confirmed by multiple amplifications which is unique
ESBL-EC in Nepal and elsewhere. The presence of car-
bapenemases like; blaNDM-1, blaIMP and blaVIM and its
co-existence with ESBLs like, blaCTX-M, blaTEM and
blaSHV in E. coli will seriously limit present and future
therapeutic options.
The study of variants of ESBL-types, their location in
mobile genetic elements (plasmids and integron ele-
ments), and clonal analysis of ESBL-EC is required.
PCR-RAPD is simple, easy, cost-effective and has short
turn-around time to answer the clonal nature of the bac-
terial isolates. PCR-RAPD was performed to study the
clonal nature of these isolates but none of the isolates
possessing similar resistance genes were grouped into
similar RAPD types. More robust tools like pulse field
gel electrophoresis and multi-locus sequence typing
would help to know the exact clonal nature of these
isolates.
Conclusion
The high prevalence of blaCTX-M-type ESBL and co-
existence of ESBLs and carbapenemases were noted in
ESBL-EC isolated from Kathmandu Medical College and
Teaching Hospital OPD and ICU patients for the first
time. Continuous monitoring of this ESBL-EC with na-
tionwide study will shed light in its dissemination and
strategy to prevent and control the further spread of
these super-bugs.
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